We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+26.01%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.4B
AUM Growth
+$351M
Cap. Flow
+$35.9M
Cap. Flow %
0.67%
Top 10 Hldgs %
42.1%
Holding
152
New
38
Increased
33
Reduced
27
Closed
23
Avg Time Held Equity + Options
6.9 quarters
Top 10 Avg Time Held Equity + Options
4.1 quarters
Top 20 Avg Time Held Equity + Options
4.5 quarters
Avg Time Held Equity only
7.4 quarters
Top 10 Avg Time Held Equity only
4.4 quarters
Top 20 Avg Time Held Equity only
4.5 quarters

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$59.7M
2
ODTX icon
Odyssey Therapeutics
ODTX
+$52.6M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$47.6M
4
COGT icon
Cogent Biosciences
COGT
+$47.6M
5
HUM icon
Humana
HUM
+$46.7M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$54.7M
2
DHR icon
Danaher
DHR
+$50.4M
3
ELVN icon
Enliven Therapeutics
ELVN
+$50.2M
4
BSX icon
Boston Scientific
BSX
+$48.8M
5
IRON icon
Disc Medicine
IRON
+$48.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.03%
2 Miscellaneous 2.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
KNSA icon
51
Kiniksa Pharmaceuticals
KNSA
$6.15B
$26.9M 0.5%
420,600
+240,001
+133% +$12.4M
2025 Q4
2 quarters
TRVI icon
52
Trevi Therapeutics
TRVI
$1.75B
$26.7M 0.49%
1,430,293
-1,024,107
-42% -$14.9M
2025 Q1
5 quarters
ABVX icon
53
CALL
Abivax
ABVX
$7.69B
$26.7M 0.49%
+200,000
New +$22.6M
2026 Q2
0 quarters
IRON icon
54
Disc Medicine
IRON
$2.17B
$26.2M 0.48%
357,535
-710,015
-67% -$48.8M
2021 Q1
21 quarters
WST icon
55
West Pharmaceutical
WST
$26.5B
$25.3M 0.47%
+70,600
New +$21.6M
2026 Q2
0 quarters
RLMD icon
56
Relmada Therapeutics
RLMD
$353M
$25.1M 0.47%
3,631,195
-1,084,669
-23% -$7.58M
2025 Q4
2 quarters
URGN icon
57
UroGen Pharma
URGN
$1.91B
$24.9M 0.46%
676,187
-199,300
-23% -$5.4M
2025 Q2
4 quarters
STRO icon
58
Sutro Biopharma
STRO
$174M
$24.7M 0.46%
743,944
-57,200
-7% -$1.78M
2026 Q1
1 quarter
SVRA icon
59
Savara
SVRA
$974M
$24.4M 0.45%
3,959,900
+3,324,900
+524% +$17.8M
2026 Q1
1 quarter
NPCE icon
60
Neuropace
NPCE
$436M
$23.9M 0.44%
1,505,125
-591,402
-28% -$9.52M
2021 Q2
20 quarters
AURA icon
61
Aura Biosciences
AURA
$636M
$23.7M 0.44%
+3,333,333
New +$23.8M
2026 Q2
0 quarters
ORIC icon
62
Oric Pharmaceuticals
ORIC
$1.2B
$21.8M 0.4%
2,015,000
-678,929
-25% -$6.16M
2025 Q1
5 quarters
HELP
63
Helus Pharma Inc. Common Stock
HELP
$753M
$21.6M 0.4%
3,271,400
-561,443
-15% -$2.81M
2025 Q4
2 quarters
BCRX icon
64
BioCryst Pharmaceuticals
BCRX
$2.07B
$18.5M 0.34%
1,852,000
+426,800
+30% +$3.86M
2025 Q3
3 quarters
BIOA icon
65
BioAge Labs
BIOA
$250M
$18.4M 0.34%
752,153
+40,342
+6% +$729K
2024 Q3
7 quarters
PTGX icon
66
CALL
Protagonist Therapeutics
PTGX
$8.96B
$18.4M 0.34%
+150,000
New +$15.7M
2026 Q2
0 quarters
LXEO icon
67
Lexeo Therapeutics
LXEO
$216M
$18.4M 0.34%
3,947,850
+345,400
+10% +$1.87M
2025 Q4
2 quarters
WHWK icon
68
Whitehawk Therapeutics
WHWK
$173M
$18M 0.33%
3,934,296
-231,704
-6% -$964K
2025 Q1
5 quarters
DFTX icon
69
Definium Therapeutics
DFTX
$4.64B
$17.2M 0.32%
365,400
-438,600
-55% -$10.8M
2025 Q3
3 quarters
SYRE icon
70
Spyre Therapeutics
SYRE
$7.44B
$16.5M 0.31%
+186,145
New +$13.6M
2026 Q2
0 quarters
CRBP icon
71
Corbus Pharmaceuticals
CRBP
$90.1M
$16.3M 0.3%
1,737,287
– –
2024 Q3
7 quarters
VERA icon
72
Vera Therapeutics
VERA
$1.94B
$15.9M 0.29%
369,596
– –
2025 Q4
2 quarters
ALMS icon
73
Alumis Inc
ALMS
$808M
$15.4M 0.29%
548,163
– –
2025 Q2
4 quarters
EYPT icon
74
EyePoint Inc
EYPT
$255M
$15.3M 0.28%
1,069,147
– –
2025 Q3
3 quarters
WAT icon
75
Waters Corp
WAT
$42.8B
$15.1M 0.28%
+40,300
New +$13.7M
2026 Q2
0 quarters
1 2
3
4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2026 Portfolio in Review

As of Q2 2026, OrbiMed held 152 positions worth $5.4B, up 7% from $5.05B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

OrbiMed's Q2 2026 filing shows 38 new, 33 increased, 27 reduced and 23 closed positions. Its largest new stake was UnitedHealth: 161,100 shares worth $67M. The largest sale was Pfizer, an estimated $54.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier, followed by Miscellaneous.

  • OrbiMed's largest Q2 2026 buy was UnitedHealth: 161,100 shares worth $67M.
  • OrbiMed added most to Cogent Biosciences in Q2 2026, an estimated $47.6M increase.
  • OrbiMed's biggest Q2 2026 reduction was Enliven Therapeutics, cutting an estimated $50.2M.
  • OrbiMed fully exited Pfizer in Q2 2026, selling an estimated $54.7M.
  • OrbiMed's ten largest holdings make up 42% of its $5.4B portfolio in Q2 2026.
  • OrbiMed opened 38 new positions and closed 23 in Q2 2026.
  • OrbiMed's portfolio value rose 7% quarter-over-quarter to $5.4B.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.